vs
Side-by-side financial comparison of Aeluma, Inc. (ALMU) and Inhibikase Therapeutics, Inc. (IKT). Click either name above to swap in a different company.
Aeluma, Inc. is the larger business by last-quarter revenue ($1.3M vs $1.0M, roughly 1.2× Inhibikase Therapeutics, Inc.). Aeluma, Inc. runs the higher net margin — -145.7% vs -1223.3%, a 1077.7% gap on every dollar of revenue.
Aeluma, Inc. is a U.S.-headquartered technology firm focused on the design, development, and production of high-performance optoelectronic components and semiconductor products. Its core offerings include photonic sensors and laser diodes, serving the LiDAR, 5G/6G communication, industrial sensing, and automotive markets across North America and the Asia-Pacific region.
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel disease-modifying therapies for neurodegenerative disorders including Parkinson's disease. It advances pipeline candidates through preclinical and clinical studies to address unmet medical needs and improve patient outcomes worldwide.
ALMU vs IKT — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $1.0M |
| Net Profit | $-1.9M | $-12.7M |
| Gross Margin | 27.8% | — |
| Operating Margin | -163.6% | -1323.3% |
| Net Margin | -145.7% | -1223.3% |
| Revenue YoY | -21.1% | — |
| Net Profit YoY | 36.0% | -5.0% |
| EPS (diluted) | $-0.11 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | $1.0M | ||
| Q3 25 | $1.4M | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $-1.9M | $-12.7M | ||
| Q3 25 | $-1.5M | $-11.9M | ||
| Q2 25 | — | $-9.9M | ||
| Q1 25 | — | $-13.7M | ||
| Q4 24 | — | $-12.1M | ||
| Q3 24 | — | $-5.8M | ||
| Q2 24 | — | $-5.0M | ||
| Q1 24 | — | $-4.6M |
| Q4 25 | 27.8% | — | ||
| Q3 25 | 49.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -163.6% | -1323.3% | ||
| Q3 25 | -116.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -145.7% | -1223.3% | ||
| Q3 25 | -107.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-0.11 | $-0.10 | ||
| Q3 25 | $-0.09 | $-0.13 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $-0.15 | ||
| Q4 24 | — | $0.88 | ||
| Q3 24 | — | $-0.65 | ||
| Q2 24 | — | $-0.66 | ||
| Q1 24 | — | $-0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $38.6M | $218.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $40.8M | $172.9M |
| Total Assets | $42.6M | $181.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $38.6M | $218.3M | ||
| Q3 25 | $25.9M | $39.1M | ||
| Q2 25 | — | $9.9M | ||
| Q1 25 | — | $19.7M | ||
| Q4 24 | — | $138.6M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $4.9M | ||
| Q1 24 | — | $7.4M |
| Q4 25 | $40.8M | $172.9M | ||
| Q3 25 | $40.9M | $72.9M | ||
| Q2 25 | — | $80.1M | ||
| Q1 25 | — | $85.7M | ||
| Q4 24 | — | $94.9M | ||
| Q3 24 | — | $-530.6K | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $6.8M |
| Q4 25 | $42.6M | $181.2M | ||
| Q3 25 | $42.7M | $79.6M | ||
| Q2 25 | — | $88.9M | ||
| Q1 25 | — | $94.3M | ||
| Q4 24 | — | $98.6M | ||
| Q3 24 | — | $4.4M | ||
| Q2 24 | — | $8.8M | ||
| Q1 24 | — | $11.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-251.0K | $-7.5M |
| Free Cash FlowOCF − Capex | $-282.0K | — |
| FCF MarginFCF / Revenue | -22.2% | — |
| Capex IntensityCapex / Revenue | 2.4% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-251.0K | $-7.5M | ||
| Q3 25 | $-815.0K | $-10.6M | ||
| Q2 25 | — | $-5.6M | ||
| Q1 25 | — | $-4.1M | ||
| Q4 24 | — | $-5.3M | ||
| Q3 24 | — | $-4.9M | ||
| Q2 24 | — | $-5.1M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | $-282.0K | — | ||
| Q3 25 | $-1.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-4.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -22.2% | — | ||
| Q3 25 | -74.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.4% | 0.0% | ||
| Q3 25 | 15.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
